Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Current Standards of Care in Glioblastoma Therapy

Open access
Department of Medical Oncology, Centro Hospitalar de São João, Porto, Portugal, FERNANDES, CATARINA, COSTA, ANDREIA, Department of Medical Oncology, Centro Hospitalar de São João, Porto, Portugal, OSÓRIO, LÍGIA, Department of Radiotherapy, Centro Hospitalar de São João, Porto, Portugal, LAGO, RITA COSTA, Department of Radiotherapy, Centro Hospitalar de São João, Porto, Portugal, LINHARES, PAULO, Department of Neurosurgery, Centro Hospitalar de São João, Porto, Portugal, Faculty of Medicine of the University of Porto, Portugal, CARVALHO, BRUNO, Department of Neurosurgery, Centro Hospitalar de São João, Porto, Portugal, Faculty of Medicine of the University of Porto, Portugal, CAEIRO, CLÁUDIA, Department of Medical Oncology, Centro Hospitalar de São João, Porto, Portugal · 2017 · Glioblastoma

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Regardless of ideal multidisciplinary treatment, including maximal surgical resection, followed by radiotherapy plus concomitant and maintenance temozolomide (TMZ), almost all patients experience tumor progression with nearly universal mortality and a median survival of less than 15 months. The addition of bevacizumab to standard treatment with TMZ revealed no increase in overall survival (OS) but improved progression-free survival (PFS). In newly diagnosed GBM, methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter has been shown to predict response to alkylating agents, as well as prognosis. Therefore, MGMT promoter status may have a crucial role in the choice of single modality treatment in fragile elderly population. No standard of care is established in recurrent or progressive GBM. Treatment alternatives may include supportive care, surgery, re-irradiation, systemic therapies, and combined modality therapy. Despite numerous clinical trials, the identification of effective therapies is complex because of the lack of appropriate control arms, selection bias, small sample sizes, and disease heterogeneity. Tumor-treating fields plus TMZ represent a major advance in the field of GBM therapy, and should be considered for patients with newly diagnosed GBM with no contraindications. As a disease with such a poor prognosis, treatment of GBM should go beyond improving survival and aim at preserving and even improving the quality of life of both the patient and the caregiver.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15586/codon.glioblastoma.2017.ch11

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 234

Metadata

Authors
Department of Medical Oncology, C. H. D. S. J., FERNANDES, C., COSTA, A., Department of Medical Oncology, C. H. D. S. J., OSÓRIO, L., Department of Radiotherapy, C. H. D. S. J., LAGO, R. C., Department of Radiotherapy, C. H. D. S. J., LINHARES, P., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CARVALHO, B., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CAEIRO, C., & Department of Medical Oncology, C. H. D. S. J.
Venue
Glioblastoma
Published
2017-09-22
Pages
197-241
OpenAlex
W2756498897
Cited by
234
References
12
FWCI
34.99
Type
book chapter
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Standards of Care in Glioblastoma Therapy. https://app.cochat.ai/papers/10.15586/codon.glioblastoma.2017.ch11
The paper
Department of Medical Oncology, C. H. D. S. J., FERNANDES, C., COSTA, A., Department of Medical Oncology, C. H. D. S. J., OSÓRIO, L., Department of Radiotherapy, C. H. D. S. J., LAGO, R. C., Department of Radiotherapy, C. H. D. S. J., LINHARES, P., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CARVALHO, B., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CAEIRO, C., & Department of Medical Oncology, C. H. D. S. J. (2017). Current Standards of Care in Glioblastoma Therapy. Glioblastoma. https://doi.org/10.15586/codon.glioblastoma.2017.ch11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.